When a patient is diagnosed with leukemia, lymphoma, or myeloma, one of the most important questions is not just what the cancer looks like under the microscope, but what is happening at the level of the chromosomes. Cytogenetics — the study of chromosomes — has been central to hematology for more than half a century, and despite the rise of DNA sequencing, it remains one of the most powerful tools we have for understanding blood cancer.
This article explains what cytogenetics is, how it is performed, what FISH testing adds, and why the results from these tests can dramatically change the diagnosis, prognosis, and treatment of a blood cancer patient.
A Short History: From Philadelphia to Precision Medicine
The story begins in 1960 in Philadelphia, where two scientists — Peter Nowell and David Hungerford — discovered an unusually small chromosome in the cells of patients with Chronic Myeloid Leukemia (CML). They called it the Philadelphia chromosome. It was the first time a specific chromosomal abnormality had been linked directly to a human cancer, and it changed how we thought about cancer forever. Cancer was no longer just a mysterious collection of misbehaving cells — it was a disease with specific genetic fingerprints that could be identified, tracked, and eventually targeted.
The Philadelphia chromosome turned out to be the result of a translocation between chromosomes 9 and 22, fusing a gene called BCR with a gene called ABL1. The resulting BCR-ABL1 fusion protein is the engine of CML. Decades later, in 2001, this discovery led to imatinib — a drug designed specifically to block BCR-ABL1. Patients who had previously faced a devastating prognosis suddenly had a pill that could control their disease indefinitely. It was the first great triumph of targeted cancer therapy, and it began with a karyotype.
What Is Cytogenetic Analysis?
Cytogenetic analysis — also called karyotyping — is the microscopic examination of a cell's chromosomes. To perform it, the laboratory grows cells from a bone marrow sample or blood in culture, arrests them at the metaphase stage of division (when chromosomes are most condensed and visible), stains them with special dyes that produce a characteristic banding pattern, and photographs them under a microscope. The chromosomes are then arranged in pairs by size and shape to produce a karyotype — a visual inventory of all 46 chromosomes.
A normal karyotype is written as 46,XX (female) or 46,XY (male). Any deviation — extra chromosomes, missing chromosomes, or rearrangements — is reported using a standardized nomenclature. For example, the Philadelphia chromosome is written as t(9;22)(q34;q11.2), meaning a translocation between the long arm of chromosome 9 at band q34 and the long arm of chromosome 22 at band q11.2.
Common Cytogenetic Findings in Blood Cancers
Different blood cancers carry characteristic chromosomal abnormalities, and recognizing them is essential. Below is a summary of some of the most important:
| Abnormality | Associated Cancer | Clinical Significance |
|---|---|---|
| t(9;22) — BCR-ABL1 | CML, Ph+ ALL | Targetable with TKIs (imatinib) |
| t(15;17) — PML-RARA | APL (a subtype of AML) | Curable with ATRA + arsenic |
| t(8;21) — RUNX1-RUNX1T1 | AML | Favourable prognosis |
| inv(16) — CBFB-MYH11 | AML | Favourable prognosis |
| del(17p) — loss of TP53 | CLL, MDS, AML | Poor prognosis |
| Complex karyotype (≥3 changes) | AML, MDS | Poor prognosis |
| t(14;18) — BCL2-IGH | Follicular lymphoma | Defining abnormality |
| t(8;14) — MYC-IGH | Burkitt lymphoma | Defining abnormality |
This table is simplified, but it illustrates an important point: the cytogenetic finding is not just a laboratory curiosity. In some cases it defines the diagnosis (you cannot diagnose CML without evidence of BCR-ABL1). In others, it predicts how the disease will behave (a favourable karyotype in AML means the patient may do well with chemotherapy alone, while an adverse karyotype usually means a stem cell transplant is being considered). And in still others, it points to a specific targeted therapy.
The Story of Acute Promyelocytic Leukemia
One of the most remarkable stories in hematology is the transformation of Acute Promyelocytic Leukemia (APL) — a subtype of AML — from one of the most deadly leukemias to one of the most curable, all because of its characteristic cytogenetic abnormality. APL is driven by the t(15;17) translocation, which fuses the PML and RARA genes. The resulting PML-RARA protein blocks the maturation of myeloid cells, causing the accumulation of immature promyelocytes.
In the 1980s, APL had a brutal prognosis — patients often died of bleeding complications before treatment could even begin. Then researchers discovered that all-trans retinoic acid (ATRA), a derivative of vitamin A, could force APL cells to mature and die. Later, arsenic trioxide was added. Today, with a regimen of ATRA and arsenic, more than 90% of APL patients achieve long-term remission — often without traditional chemotherapy. None of this would have been possible without cytogenetic testing to identify t(15;17) in the first place.
The Limitations of Karyotyping
Despite its power, conventional karyotyping has important limitations. It requires living, dividing cells — so failed cultures mean no result. It only detects relatively large abnormalities, typically 5-10 million base pairs or more. Small deletions, point mutations, and cryptic translocations (those that look normal under the microscope but are present at the DNA level) cannot be seen. And the process takes time — typically 1-3 weeks for results.
This is where FISH comes in.
FISH: Fluorescence In Situ Hybridization
FISH is a technique that uses fluorescently labelled DNA probes to detect specific chromosomal regions directly in cells. Because it targets specific sequences, FISH can identify abnormalities that conventional karyotyping misses. It is faster (results often in 24-48 hours), more sensitive, and does not require dividing cells — so it can be performed on fixed tissue, peripheral blood, or even archived specimens.
In practice, FISH is usually targeted to specific abnormalities the hematologist suspects. For a patient with suspected CML, a BCR-ABL1 probe will show two normal signals in a healthy cell and a fusion signal in a cancer cell. For a patient with CLL, a panel might include probes for del(13q), trisomy 12, del(11q), and del(17p) — all of which have prognostic significance.
Clinical Impact: Why It Matters for Patients
For patients, cytogenetics and FISH results can change everything. Consider a patient diagnosed with AML. If cytogenetics reveals t(8;21), the prognosis is favourable and the likely plan is chemotherapy without transplant. If it reveals complex karyotype or monosomy 7, the prognosis is adverse and a transplant will usually be recommended. If it reveals t(15;17), the diagnosis shifts to APL, and ATRA/arsenic treatment begins immediately — often before any other information is available, because delay in APL can be fatal.
For a patient with CLL, FISH for del(17p) is essential. A patient with del(17p) will not respond well to standard chemo-immunotherapy and should receive a BTK inhibitor or BCL2 inhibitor instead. For a patient with multiple myeloma, FISH is used to identify high-risk features like t(4;14), t(14;16), or del(17p) — which affect treatment intensity and transplant decisions.
What Patients Should Ask
If you or a loved one has been diagnosed with a blood cancer, it is entirely reasonable to ask: has cytogenetic analysis been performed? Has FISH been performed, and for which probes? What were the results? What do they mean for my prognosis and treatment?
These are not intrusive questions — they are core to understanding your diagnosis. Modern hematology is built on the integration of morphology, flow cytometry, cytogenetics, and molecular testing. Any one test alone gives an incomplete picture. If your diagnosis was made without cytogenetic data, a second opinion and additional testing may be worth considering before committing to a treatment plan.
Chromosomes are the archives of a cell's history. When something goes wrong in a blood cell, the chromosomes often hold the clue. Learning to read that clue is one of the most important things hematologists do — and for patients, it is one of the most valuable gifts that modern medicine can offer.